{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:40:09Z","timestamp":1786466409593,"version":"build-2736575974"},"reference-count":18,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Pure red cell aplasia (PRCA) is a rare single-lineage bone marrow (BM) failure characterized by anemia with profound reticulocytopenia and severe reduction of erythroid precursors. PRCA is heterogeneous, and diagnosis requires extensive evaluation to distinguish primary from secondary causes, such as thymoma, autoimmune diseases, T-cell large granular lymphocyte expansion, and myelodysplastic syndrome (MDS), the differential diagnosis of which is particularly challenging. Evidence guiding management remains limited because of the rarity of the disease and the lack of prospective studies. We analyzed 121 acquired adult PRCA (excluding Parvovirus B19-associated PRCA) cases across 14 European centers. Secondary forms accounted for 78% of diagnoses, mostly thymoma (23%) or MDS (21%). In a subset of patients, BM immunohistochemistry demonstrated significant depositions of C3, C4d, immunoglobulin M (IgM), and IgG, reducing after immunosuppression. Next-generation sequencing was performed in half of the patients, 36% of whom presented mutations predominantly related to clonal hematopoiesis, except in MDS-associated cases, which often carried multiple non-clonal hematopoiesis mutations. Immunosuppression represented the backbone of therapy: cyclosporine A (CyA) was the most effective agent, with 61% overall response rate (47% complete) and better outcomes when initiated earlier; mammalian target of rapamycin inhibitors (mTORi) showed promising activity as second-line therapy, with responses in 71% of the patients, including CyA-refractory cases. Mortality reached 30%, predominantly because of infectious complications, and was significantly higher in MDS-associated cases. PRCA remains a diagnostically challenging and clinically heterogeneous disorder in which integration of molecular analyses may refine diagnostic accuracy and patient stratification. Immunosuppression remains the mainstay of treatment, with CyA being a reliable first-line treatment and mTORi emerging as encouraging rescue options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019525","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:12:53Z","timestamp":1779883973000},"page":"5285-5292","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-3840","authenticated-orcid":false,"given":"Francesco","family":"Versino","sequence":"first","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[{"name":"3Internal Medicine Department, Henri Mondor University Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-3014","authenticated-orcid":false,"given":"Jennifer","family":"Vidler","sequence":"additional","affiliation":[{"name":"4Department of Haematological Medicine, King\u2019s College Hospital, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-7362","authenticated-orcid":false,"given":"Salvador","family":"Pay\u00e1n-Pern\u00eda","sequence":"additional","affiliation":[{"name":"5Hematology Department, Virgen del Roc\u00edo University Hospital, Instituto de Biomedicina de Sevilla (IBiS)-Spanish National Research Council, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roochi","family":"Trikha","sequence":"additional","affiliation":[{"name":"4Department of Haematological Medicine, King\u2019s College Hospital, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyans","family":"Gandhi","sequence":"additional","affiliation":[{"name":"4Department of Haematological Medicine, King\u2019s College Hospital, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Gogoi","sequence":"additional","affiliation":[{"name":"4Department of Haematological Medicine, King\u2019s College Hospital, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-7825","authenticated-orcid":false,"given":"Manujasri","family":"Wimalachandra","sequence":"additional","affiliation":[{"name":"4Department of Haematological Medicine, King\u2019s College Hospital, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Racchi","sequence":"additional","affiliation":[{"name":"6Hematology Unit, Villa Scassi Hospital, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Lupo-Stanghellini","sequence":"additional","affiliation":[{"name":"7Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1382-5496","authenticated-orcid":false,"given":"Sabrina","family":"Giammarco","sequence":"additional","affiliation":[{"name":"8Hematology Unit, Policlinico Gemelli Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-6425","authenticated-orcid":false,"given":"Maria","family":"Marina Arguello","sequence":"additional","affiliation":[{"name":"9Hematology Unit, Pr\u00edncipe de Asturias University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-6048","authenticated-orcid":false,"given":"Mara","family":"Memoli","sequence":"additional","affiliation":[{"name":"10Hematology and Hematopoietic Stem Cell Transplant Unit, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-0738","authenticated-orcid":false,"given":"Andreas","family":"Glenth\u00f8j","sequence":"additional","affiliation":[{"name":"11Hematology Unit, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0732-0616","authenticated-orcid":false,"given":"Gabriele","family":"Merati","sequence":"additional","affiliation":[{"name":"12Hematology Unit, Hospital Alessandro Manzoni, Lecco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-1604","authenticated-orcid":false,"given":"Yamuna Wasanthi","family":"Wickramasinghe","sequence":"additional","affiliation":[{"name":"4Department of Haematological Medicine, King\u2019s College Hospital, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0713-6506","authenticated-orcid":false,"given":"Aparna","family":"Chitharanjan","sequence":"additional","affiliation":[{"name":"4Department of Haematological Medicine, King\u2019s College Hospital, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mylene","family":"Hemmer","sequence":"additional","affiliation":[{"name":"3Internal Medicine Department, Henri Mondor University Hospital, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[{"name":"13PROMISE Department, University of Palermo, and Hematology and Rare Disease Unit, \u201cCervello\u201d Hospital, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Jim\u00e9nez-Jambrina","sequence":"additional","affiliation":[{"name":"5Hematology Department, Virgen del Roc\u00edo University Hospital, Instituto de Biomedicina de Sevilla (IBiS)-Spanish National Research Council, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Achille","family":"Brioschi","sequence":"additional","affiliation":[{"name":"14Hematology Unit, San Gerardo Hospital, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-4911","authenticated-orcid":false,"given":"Antonio","family":"Palma-Vallelano","sequence":"additional","affiliation":[{"name":"15Hematology Unit, Juan Ram\u00f3n Jim\u00e9nez Hospital, Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-1816","authenticated-orcid":false,"given":"Tomas Jose","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[{"name":"16Hematology Unit, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Clissa","sequence":"additional","affiliation":[{"name":"17Hematology Unit, Policlinico G.B. Rossi, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bortolotti","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7727-2766","authenticated-orcid":false,"given":"Giacinto Luca","family":"Pedone","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5979-7841","authenticated-orcid":false,"given":"Giorgio Alberto","family":"Croci","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-9944","authenticated-orcid":false,"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin","family":"Kulasekararaj","sequence":"additional","affiliation":[{"name":"4Department of Haematological Medicine, King\u2019s College Hospital, King\u2019s College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-8379","authenticated-orcid":false,"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[{"name":"1Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"19","key":"2026081110263638200_bib1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJM199705083361906","article-title":"The pathophysiology of acquired aplastic anemia","volume":"336","author":"Young","year":"1997","journal-title":"N Engl J Med"},{"issue":"21","key":"2026081110263638200_bib2","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026081110263638200_bib3","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S2352-3026(24)00063-2","article-title":"Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement","volume":"11","author":"Wlodarski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026081110263638200_bib4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s13023-024-03490-6","article-title":"Diagnosis of Diamond-Blackfan anemia in adulthood: case series and review of the literature","volume":"19","author":"Versino","year":"2024  19","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2026081110263638200_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.1994.tb06743.x","article-title":"Parvovirus B19 as a cause of acquired chronic pure red cell aplasia","volume":"87","author":"Frickhofen","year":"1994","journal-title":"Br J Haematol"},{"issue":"1","key":"2026081110263638200_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/rheumatology\/keab363","article-title":"Pure red cell aplasia in systemic lupus erythematosus, a nationwide retrospective cohort and review of the literature","volume":"61","author":"Lobbes","year":"2021","journal-title":"Rheumatology"},{"issue":"7","key":"2026081110263638200_bib7","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood.V87.7.3000.bloodjournal8773000","article-title":"Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities","volume":"87","author":"Lacy","year":"1996","journal-title":"Blood"},{"issue":"8","key":"2026081110263638200_bib8","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.21037\/jtd.2018.07.14","article-title":"Pure red cell aplasia associated with thymoma: a report of a single-center experience","volume":"10","author":"Moriyama","year":"2018","journal-title":"J Thorac Dis"},{"issue":"2","key":"2026081110263638200_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3324\/haematol.2017.175810","article-title":"Rational management approach to pure red cell aplasia","volume":"103","author":"Balasubramanian","year":"2018","journal-title":"Haematologica"},{"issue":"15","key":"2026081110263638200_bib10","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood.2021010898","article-title":"How I manage acquired pure red cell aplasia in adults","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026081110263638200_bib11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.13376","article-title":"Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004\/2006 by the Japan PRCA collaborative study group","volume":"169","author":"Hirokawa","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"2026081110263638200_bib12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00277-004-0894-3","article-title":"Myelodysplasia masquerading as parvovirus-related red cell aplasia with giant pronormoblasts","volume":"83","author":"Au","year":"2004","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"2026081110263638200_bib13","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2023-190395","article-title":"Pathogenetic subtypes of pure red cell aplasia and therapeutic management strategies: a single centre experience in the United Kingdom of 75 patients over 10 years","volume":"142","author":"Gogoi","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026081110263638200_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/bloodadvances.2024014984","article-title":"Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study","volume":"9","author":"Fattizzo","year":"2025;  11","journal-title":"Blood Adv"},{"issue":"9","key":"2026081110263638200_bib15","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1007\/s00277-025-06638-x","article-title":"Comprehensive analysis of the clinical feature, myeloid neoplasm-related gene mutation profiles and T cell diversity acquired pure red cell aplasia","volume":"104","author":"Gong","year":"2025","journal-title":"Ann Hematol"},{"issue":"8","key":"2026081110263638200_bib16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3324\/haematol.11192","article-title":"Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group","volume":"92","author":"Sawada","year":"2007","journal-title":"Haematologica"},{"issue":"21","key":"2026081110263638200_bib17","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1182\/bloodadvances.2023010587","article-title":"Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis","volume":"7","author":"Lobbes","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2026081110263638200_bib18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41375-022-01532-1","article-title":"Sirolimus is effective for refractory\/relapsed\/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial","volume":"36","author":"Huang","year":"2022","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5285\/2535696\/blooda_adv-2025-019525-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5285\/2535696\/blooda_adv-2025-019525-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:31Z","timestamp":1786463011000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5285\/568746\/Clinical-heterogeneity-and-outcome-of-acquired"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019525","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,30]]}}}